John Tchelingerian, PhD

PannTheraPi is the first pharmaceutical company dedicated to the development of Pannexin 1 channel blocker drugs for the treatment of brain and nervous diseases, aiming for better efficacy and better tolerance than current drugs. PannTheraPi offers breakthrough innovation for the two main issues in development of current drugs in neurological diseases: - Innovative target adressing the root cause of the diseases - Representative non-clinical model using human brain tissues PanTheraPi generates repurposed and new chemical entities drugs.

Siamo una compagnia biofarmaceutica che ha lo scopo di scoprire e sviluppare composti innovativi per risolvere la maggior parte delle malattie neurodegenerative.

AI-powered software for accelerating clinical trials in ophthalmology to improve efficiency, decrease costs, enhance patient experience.

Rtec is dedicated to developing disruptive innovation to recycle plastic waste. Our principal innovation is a novel plastic melting technology capable of turning any post-industrial and post-consumer thermoplastic waste, in any form into new products in one simple and efficient step. Graduates of the La Trobe University & Fraunhofer Institute TILTi5 program 2022-2023. Graduates of the CSIRO Inovate to Grow program -2020. Australian finalists in the Entrepreneurship World Cup (EWC) 2020 Graduates of the La Trobe University Business Accelerator Program (LTAP) 2019-2020.

Lounjee connects members of a professional network based on their professional goals and interests. Join hundreds of community by industry/sector/topic!

SCI-BRAIN helps you identify and map experts on any topic. We develop business and scientific intelligence solutions to grow your business.

MElkin pharmaceuticals is a biopharmaceutical company identifying and developing innovative new treatments for cancer and brain diseases that are associated with aberrant activation of the MAPKinase/ERK signaling pathway. Founded in 2015, the company is currently engaged in the preclinical development of the PepFos lead compound for cancer treatment.

PannTheraPi is the first pharmaceutical company dedicated to the development of Pannexin 1 channel blocker drugs for the treatment of brain and nervous diseases, aiming for better efficacy and better tolerance than current drugs. PannTheraPi offers breakthrough innovation for the two main issues in development of current drugs in neurological diseases: - Innovative target adressing the root cause of the diseases - Representative non-clinical model using human brain tissues PanTheraPi generates repurposed and new chemical entities drugs.

Siamo una compagnia biofarmaceutica che ha lo scopo di scoprire e sviluppare composti innovativi per risolvere la maggior parte delle malattie neurodegenerative.

AI-powered software for accelerating clinical trials in ophthalmology to improve efficiency, decrease costs, enhance patient experience.

Rtec is dedicated to developing disruptive innovation to recycle plastic waste. Our principal innovation is a novel plastic melting technology capable of turning any post-industrial and post-consumer thermoplastic waste, in any form into new products in one simple and efficient step. Graduates of the La Trobe University & Fraunhofer Institute TILTi5 program 2022-2023. Graduates of the CSIRO Inovate to Grow program -2020. Australian finalists in the Entrepreneurship World Cup (EWC) 2020 Graduates of the La Trobe University Business Accelerator Program (LTAP) 2019-2020.

The Connecting Architects provides strategic, business development and external growth advisory services to investors and innovative companies to support their growth and global scale up. Full service platform with global partners in US, EU and Asia for both entrepreneurial and advisory services to support deal-making for early and mid-stage companies and venture building. Broad expertise in life sciences, biotech, health tech, digital health and food tech. A few case studies: • Advised a Swedish biopharma, TikoMed AB, on a strategic collaboration with IQVIA. • Advised on first international institutional capital raise for a Health Tech company in the ophthalmology space. • Advising an Italian early-stage biotech developing a neuroprotective treatment for glaucoma • Advising a Dutch biotech on International Series A and business development and licensing. • Advised an EU biotech on bridge financing from existing and new (Asian) investors.